Elevance Health Reaffirms 2025 Earnings Guidance

An announcement from Elevance Health ( (ELV) ) is now available.

Elevance Health, Inc. announced that its officers will meet with investors to reaffirm the company’s earnings guidance for the full year 2025. The company expects adjusted shareholders’ earnings to range from $34.15 to $34.85 per diluted share, excluding net unfavorable items, and anticipates that 60% of these earnings will be realized in the first half of 2025. This guidance reflects the company’s current assessment of market conditions, regulatory landscape, and operational performance, though actual results may vary based on changes in business factors or assumptions.

The most recent analyst rating on (ELV) stock is a Buy with a $600.00 price target. To see the full list of analyst forecasts on Elevance Health stock, see the ELV Stock Forecast page.

Spark’s Take on ELV Stock

According to Spark, TipRanks’ AI Analyst, ELV is a Outperform.

Elevance Health’s overall score of 71 reflects a strong financial foundation with consistent revenue growth and solid profitability, though offset by technical weaknesses and challenges in the Medicaid segment. Valuation is fair, but not compelling enough alone to drive a strong buy recommendation. The earnings call provided positive strategic updates, yet acknowledged ongoing cost pressures. Overall, this positions Elevance Health as a stable investment with areas for improvement, especially in technical momentum and cost management.

To see Spark’s full report on ELV stock, click here.

More about Elevance Health

Elevance Health, Inc. operates in the healthcare industry, providing a range of health benefits and services with a focus on medical and pharmacy services.

Average Trading Volume: 1,773,005

Technical Sentiment Signal: Sell

Current Market Cap: $84.95B

Learn more about ELV stock on TipRanks’ Stock Analysis page.